Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:SUNPHARMA

SUN PHARMACEUTICAL IND L

Healthcare › Pharmaceuticals & Biotechnology·NIFTY 100NIFTY 200NIFTY 50NIFTY 500+8
₹1,757.50
at close · 28 Oct 2026
▲ 6.30 (+0.36%)

Latest filings

Next results: Fri, 30 Oct · Financial Results
  1. Sun Pharma allots INR 7,816 crore of privately placed NCDs · Fund Raising
  2. UNLOXCYT long-term data to be presented at ESMO 2026 · Compliance
  3. UNLOXCYT gains expanded US cancer-guideline status · Business Updates
All filings ↓
Ask Nexa about SUN PHARMACEUTICAL IND L

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Manufactures and markets pharmaceutical formulations across four primary geographies: India, the United States, emerging markets, and the rest of the world. India formulations are the largest stream, with Q1 FY27 sales of Rs 54,749m and the #1 position in the Indian Pharmaceutical Market at 8.5% share. The US business reported US$427m in Q1 FY27 (-9.7% YoY), split between generics under pricing pressure from Lenalidomide erosion and specialty Innovative Medicines, which crossed US$1bn in US sales in FY26 and is now larger than US generics. Global Innovative Medicines, led by Ilumya (IL-23 immunology biologic), Odomzo, Leqselvi (alopecia), and Unloxcyt (oncology), contributed 21.9% of Q1 FY27 sales and grew 12.4% YoY at US$351m. Emerging markets generated US$311m in Q1 FY27 (+4.2%) and ROW generated US$218m. It is also the #2 generic Semaglutide injectable player in India, with approvals secured in Brazil and South Africa. The pending Organon acquisition (closing targeted Q4 FY27) would add a women's health and established brands portfolio, and Innovcare Lifesciences was acquired for Rs 271.2 crores to strengthen the India product range.

Operating scale
India formulations rank and share
#1 with 8.5% IPM market shareQ1 FY27
US Innovative Medicines sales
Crossed US$1bn for first timeFY26
Leqselvi US prescribers
Surpassed 1,000 prescribersJune 2026
R&D spend
Rs 8,264m (5.4% of sales)Q1 FY27
Brazil semaglutide market size
~US$413m (IQVIA)FY26
Semaglutide rank in India
#2 generic injectable playerQ1 FY27
Who pays it
Patients via retail pharmacy and hospital channels in India (IPM); US prescribers, specialty pharmacies, and Medicare Part B for biologics; patients in emerging markets through branded generic distribution
Biggest cost
Other operating expenses at 30.4% of revenue are the largest cost line; materials (API and formulations) at 12.6% and employee costs at 19.5% round out the cost base
Kind of business
Diversified specialty pharmaceuticals spanning branded generics, US generics, and a growing global Innovative Medicines franchise
Where it sits
Largest pharmaceutical company in India at 8.5% IPM share; US Innovative Medicines franchise crossed US$1bn in FY26 and is now larger than the US generics business
Market Cap
₹4.22 L Cr
P / E (TTM)
34.9×
EV / EBITDA
21.5×
Div Yield
0.93%
Growth
11.8%▲
Revenue 5y CAGR
PAT +38.3% · EBITDA +29.7%
Quality
16.5%▲
ROCE (5y median)
ROE 14.3% (5y median) · margin 31.5%
Leverage
0.05·
Debt / Equity · low
Net cash ₹5,689 Cr
Revenue FY21→FY26
1.7×▲
Margin +12.9 pts
₹33,498 Cr → ₹58,462 Cr
Cash conversion
1.20×▲
Operating cash ÷ profit · 5 yrs
₹52,570 Cr on ₹43,986 Cr
Moves on a normal day
0.64%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#90/158
P/B#115/163
ROCE#46/183
ROE#53/166
Debt / Equity#67/166
EBITDA margin#27/165
Revenue growth#93/161
Profit growth#84/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Profit compounding 38% a year over 5 years
Profit grew in every one of the last 5 years
Returns on capital 16.5% (5-year median)
#46 of 183 in Pharmaceuticals on the latest reported figures · up from 5.7% in FY21
Debt at 0.05× equity
lower than 60% of its 166 Pharmaceuticals peers
Over 5 years it reported ₹43,986 Cr of profit and ₹52,570 Cr of operating cash — 1.20×
Profit is converting into cash
Pays out 34% of profit as dividend
Concerns
Heavy working capital — 123 days of cash tied up
EPS grew slower than profit — the share count rose (bonus or dilution)

Charts

How has the market priced it — with filings on the timeline?

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from SUN PHARMACEUTICAL IND L's filed financials and exchange disclosures

What does SUN PHARMACEUTICAL IND L do?

SUN PHARMACEUTICAL IND L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SUNPHARMA.

Is SUN PHARMACEUTICAL IND L profitable?

Yes. Over the trailing twelve months SUN PHARMACEUTICAL IND L reported a net profit of ₹12,117 Cr on revenue of ₹59,911 Cr.

Does SUN PHARMACEUTICAL IND L pay a dividend?

Yes. The dividend yield is 0.93% at the current price. It paid out 34% of its profit as dividend in FY26.

Is SUN PHARMACEUTICAL IND L debt-free?

On a net basis, yes. It reported borrowings of ₹4,082 Cr on its 31 Mar 2026 balance sheet, but holds ₹5,689 Cr more cash than debt.

Is SUN PHARMACEUTICAL IND L expensive compared with its peers?

On trailing P/E, SUN PHARMACEUTICAL IND L ranks 90 of 158 in Pharmaceuticals — cheaper than 43% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the SUN PHARMACEUTICAL IND L share price move in a day?

On a typical session SUN PHARMACEUTICAL IND L moves 0.64% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

When are SUN PHARMACEUTICAL IND L's next results?

Financial Results on Fri, 30 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track SUN PHARMACEUTICAL IND L's announcements?

Every NSE and BSE filing by SUN PHARMACEUTICAL IND L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.